Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery. Issue 4 (29th November 2021)

• Record Type: Journal Article
• Authors: Mangieri, Christopher W.; Moaven, Omeed; Valenzuela, Cristian D.; Erali, Richard A.; Votanopoulos, Konstantinos I.; Shen, Perry; Levine, Edward A.
• Is Part Of: Journal of surgical oncology. Volume 125:Issue 4(2022)
• Page Start: 703
• Page End: 711
• Publication Date: 2021-11-29
• Subjects: cytoreductive surgery -- hyperthermic intraperitoneal chemotherapy -- peritoneal surface malignancy; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26759
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Introduction: Hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery (CRS) is typically reserved for a complete or optimal cytoreduction. There is the potential for therapeutic effect of HIPEC with an incomplete cytoreduction, particularly for near optimal cytoreductions. Methods: Retrospective review of incomplete cytoreductions (R2b, R2c) for appendiceal and colorectal primaries. Primary endpoints were overall survival (OS) and progression‐free survival (PFS). Subgroup analysis for primary etiology and specific cytoreductive score. Results: A total of 121 cases of incomplete CRS, 74 CRS alone, and 47 CRS‐HIPEC. For the entire study group there was a survival benefit with HIPEC. OS and PFS were 2.3 versus 1.4 ( p = 0.001) and 1.6 versus 0.7 ( p < 0.0001) respectively for cases with and without HIPEC. Subgroup analysis of appendiceal neoplasms, 43 CRS‐HIPEC and 50 CRS alone, found HIPEC benefit persisted; OS and PFS were 2.4 versus 1.5 ( p = 0.016) and 1.7 versus 0.8 ( p < 0.0001), respectively for cases with and without HIPEC. Benefit most pronounced in low‐grade cases with doubling of the OS and PFS ( p = 0.004). With colorectal primary cases, 10 CRS‐HIPEC and 18 CRS alone, no difference in OS and PFS. When stratifying out by cytoreduction scores, R2b and R2c, HIPEC only provided a benefit for R2b cases; OS and PFS for R2b cases were 2.28 versus 1.01 ( p = 0.011) and 1.67 versus 0.75 ( p = 0.001), respectively for cases with and without HIPEC. Conclusion: HIPEC has utility for incomplete cytoreductions with appendiceal neoplasms, greatest effect with low‐grade appendiceal neoplasms. HIPEC is only beneficial for near optimal cytoreductions (R2b).